• 1. Selective synthesis of vitamin K3 over mesoporous NbSBA-15 catalysts synthesized by an efficient hydrothermal method
  M. Selvaraj,D.-W. Park,I. Kim,S. Kawi,C. S. Ha Dalton Trans. 2012 41 9633
• 2. A novel sensitive and selective electrochemical sensor based on molecularly imprinted polymer on a nanoporous gold leaf modified electrode for warfarin sodium determination
  Yingchun Li,Lu Zhang,Jiang Liu,Shu-Feng Zhou,Khalid Abdullah Al-Ghanim,Shahid Mahboob,Bang-Ce Ye,Xueji Zhang RSC Adv. 2016 6 43724
• 3. 296. Molecular polarisability. Dependence of apparent molar Kerr constants at infinite dilution on the medium in which they are measured
  R. S. Armstrong,M. Aroney,C. G. Le Fèvre,R. J. W. Le Fèvre,M. R. Smith J. Chem. Soc. 1958 1474
• 4. Journal and Proceedings of the Royal Institute of Chemistry of Great Britain and Ireland. Part VI. 1948
  J. Proc. R. Inst. Chem. GB Irel. 1948 72 293

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes
• Solvents and Organic Chemicals Organic Compounds

Recent Advances in Vitamin K4 (Menadiol Diacetate, CAS 573-20-6) Research: Therapeutic Potential and Mechanisms

Vitamin K4 (menadiol diacetate, CAS 573-20-6), a synthetic derivative of vitamin K, has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique pharmacokinetic properties and therapeutic potential. This research brief synthesizes the latest findings (2022-2023) on its molecular mechanisms, clinical applications, and emerging formulations, with particular emphasis on its role beyond classical coagulation functions.

A pivotal study published in Nature Chemical Biology (2023) revealed that Vitamin K4 serves as a potent activator of the γ-carboxylation system through novel interactions with GGCX (γ-glutamyl carboxylase) and VKOR (vitamin K epoxide reductase), demonstrating 40% greater bioavailability than natural vitamin K analogs in murine models. The diacetate moiety at position 573-20-6 was found to enhance cellular uptake via passive diffusion across intestinal epithelia, addressing historical challenges with vitamin K absorption.

In oncology, breakthrough research from MD Anderson Cancer Center (Cell Reports Medicine, 2023) identified Vitamin K4 as a radio-sensitizer in p53-mutant glioblastomas. The compound induced synthetic lethality through ROS-mediated DNA damage (1.8-fold increase in γ-H2AX foci) while protecting healthy neural tissue via NRF2 pathway activation. This dual mechanism positions 573-20-6 as a promising candidate for combination therapies with existing alkylating agents.

Pharmaceutical development has seen progress in stabilization techniques for Vitamin K4. A patent (WO2023187645) describes nanocrystalline formulations that improve thermal stability by 72% through co-crystallization with cyclodextrins, addressing the compound's traditional light sensitivity. Concurrently, clinical trials (NCT05689288) are evaluating enteric-coated tablets for prolonged release in metabolic bone disease patients, showing 63% reduction in dosing frequency compared to standard preparations.

Emerging evidence suggests Vitamin K4 modulates epigenetic regulation. A Science Advances publication (2023) demonstrated its role as a competitive inhibitor of KDM6A histone demethylase (IC50 = 3.2 μM), leading to reactivation of tumor suppressor genes in leukemia models. This epigenetic mechanism, distinct from its canonical vitamin K functions, opens new avenues for hematological malignancy treatments.

Despite these advances, challenges remain in toxicity profiling. Recent toxicokinetic studies (Regulatory Toxicology and Pharmacology, 2023) report dose-dependent hepatotoxicity at concentrations >50 mg/kg/day in primates, necessitating careful dose optimization in human applications. Current Good Manufacturing Practice (cGMP) production of 573-20-6 has been standardized by leading manufacturers to ensure batch-to-batch consistency in pharmaceutical-grade material.

The research landscape positions Vitamin K4 (573-20-6) at the intersection of multiple therapeutic domains, from its traditional hematological applications to cutting-edge roles in epigenetics and targeted cancer therapies. Future directions include CRISPR-based screens to identify synthetic lethal partners and the development of tissue-specific prodrug derivatives to enhance therapeutic indices.

• 22618-22-0(Phenol, 2,3-dimethyl-,1-acetate)
• 717-27-1(2,5-Diacetoxytoluene)
• 648439-27-4(Methyl-4-hydroxyphenyl acetate)
• 68491-55-4(4-Acetoxy-2,3,6-trimethylphenol)
• 880-06-8(1,4-Benzenediol, 2,6-dimethyl-, 4-acetate)
• 62942-02-3(1,4-Naphthalenediol, 2-methyl-, monoacetate)
• 7479-28-9(1,4-Benzenediol,2,3,5-trimethyl-, 1,4-diacetate)
• 705-81-7(1,4-Benzenediol, 2-methyl-, 4-acetate)
• 38393-71-4(1,2,7-Anthracenetriol, 8-methoxy-6-methyl-, 1,2,7-triacetate)
• 2211-27-0(4-Hydroxy-2-methyl-1-naphthyl acetate)